Introduction {#s1}
============

During development, well-orchestrated cellular processes guide cells from diverse lineages to integrate into the primitive heart tube and establish rhythmic and coordinated contractions. While many genes and pathways important for cardiac morphogenesis have been identified, molecular mechanisms governing embryonic cardiac rhythmicity are poorly understood. The findings that Ca^2+^ waves traveling across the heart soon after the formation of the primitive heart tube ([@bib11]) and that loss of function of key Ca^2+^ regulatory proteins, such as the L-type Ca^2+^ channel, Na/K−ATPase and sodium-calcium exchanger 1 (NCX1), severely impairs normal cardiac function ([@bib47]; [@bib54]; [@bib22]; [@bib35]), indicate an essential role for Ca^2+^ handling in the regulation of embryonic cardiac function.

Ca^2+^ homoeostasis in cardiac muscle cells is tightly regulated at the temporal and spatial level by a subcellular network involving multiple proteins, pathways, and organelles. The release and reuptake of Ca^2+^ by the sarcoplasmic reticulum (SR), the largest Ca^2+^ store in cardiomyocytes, constitutes the primary mechanism governing the contraction and relaxation of the heart. Ca^2+^ influx after activation of the L-type Ca^2+^ channel in the plasma membrane induces the release of Ca^2+^ from the SR via ryanodine receptor (RyR) channels, which leads to an increase of the intracellular Ca^2+^ concentration and cardiac contraction. During diastolic relaxation, Ca^2+^ is transferred back into the SR by the SR Ca^2+^ pump or extruded from the cell through NCX1. Defects in cardiac Ca^2+^ handling and Ca^2+^ overload, for example during cardiac ischemia/reperfusion or in long QT syndrome, are well known causes of contractile dysfunction and many types of arrhythmias including early and delayed afterdepolarizations and Torsade des pointes ([@bib4]; [@bib12]; [@bib57]; [@bib28]).

Ca^2+^ crosstalk between mitochondria and ER/SR has been noted in many cell types and the voltage-dependent anion channel (VDAC) and the mitochondrial Ca^2+^ uniporter (MCU) serve as primary routes for Ca^2+^ entry through the outer and inner mitochondrial membranes, respectively ([@bib44]; [@bib2]; [@bib53]; [@bib3]; [@bib18]). In the heart, mitochondria are tethered to the SR and are located in close proximity to Ca^2+^ release sites ([@bib26]; [@bib6]; [@bib30]). This subcellular architecture exposes the mitochondria near the Ca^2+^ release sites to a high local Ca^2+^ concentration that is sufficient to overcome the low Ca^2+^ affinity of MCU and facilitates Ca^2+^ crosstalk between SR and mitochondria ([@bib26]; [@bib20]; [@bib33]). Increase of the mitochondrial Ca^2+^ concentration enhances energy production during higher workload and dysregulation of SR-mitochondrial Ca^2+^ signaling results in energetic deficits and oxidative stress in the heart and may trigger programmed cell death ([@bib7]; [@bib37]; [@bib33]). However, whether SR-mitochondrial Ca^2+^ crosstalk also contributes significantly to cardiac Ca^2+^ signaling during excitation-contraction coupling requires further investigation.

In zebrafish, the *tremblor* (*tre*) locus encodes a cardiac-specific isoform of the Na^+^/Ca^2+^ exchanger 1, NCX1h (also known as slc8a1a) ([@bib22]; [@bib35]). The *tre* mutant hearts lack rhythmic Ca^2+^ transients and display chaotic Ca^2+^ signals in the myocardium leading to unsynchronized contractions resembling cardiac fibrillation ([@bib35]). In this study, we used *tre* as an animal model for aberrant Ca^2+^ handling-induced cardiac dysfunction and took a chemical genetic approach to dissect the Ca^2+^ regulatory network important for maintaining cardiac rhythmicity. A synthetic compound named efsevin was identified from a suppressor screen due to its potent ability to restore coordinated contractions in *tre*. Using biochemical and genetic approaches we show that efsevin interacts with VDAC2 and potentiates its mitochondrial Ca^2+^ transporting activity and spatially and temporally modulates cytosolic Ca^2+^ signals in cardiomyocytes. The important role of mitochondrial Ca^2+^ uptake in regulating cardiac rhythmicity is further supported by the suppressive effect of VDAC2 and MCU overexpression on cardiac fibrillation in *tre*.

Results and discussion {#s2}
======================

Identification of a chemical suppressor of *tre* cardiac dysfunction {#s2-1}
--------------------------------------------------------------------

Homozygous *tre* mutant embryos suffer from Ca^2+^ extrusion defects and manifest chaotic cardiac contractions resembling fibrillation ([@bib22]; [@bib35]). To dissect the regulatory network of Ca^2+^ handling in cardiomyocytes and to identify mechanisms controlling embryonic cardiac rhythmicity, we screened the BioMol library and a collection of synthetic compounds for chemicals that are capable of restoring heartbeat either completely or partially in *tre* embryos. A dihydropyrrole carboxylic ester compound named efsevin was identified based on its ability to restore persistent and rhythmic cardiac contractions in *tre* mutant embryos in a dose-dependent manner ([Figure 1A,E](#fig1){ref-type="fig"}, and [Videos 1--4](#video1 video2 video3 video4){ref-type="other"}). To validate the effect of efsevin, we assessed cardiac performance of wild type, *tre* and efsevin-treated *tre* embryos ([@bib41]). Fractional shortening of efsevin treated *tre* mutant hearts was comparable to that of their wild type siblings and heart rate was restored to approximately 40% of that observed in controls ([Figure 1B--D](#fig1){ref-type="fig"}). Periodic local field potentials accompanying each heartbeat were detected in wild type and efsevin-treated *tre* embryos using a microelectrode array ([Figure 1F--H](#fig1){ref-type="fig"}). Furthermore, while only sporadic Ca^2+^ signals were detected in *tre* hearts, in vivo Ca^2+^ imaging revealed steady Ca^2+^ waves propagating through efsevin-treated *tre* hearts ([Figure 1I](#fig1){ref-type="fig"}, [Videos 5--7](#video5 video6 video7){ref-type="other"}), demonstrating that cardiomyocytes are functionally coupled and that efsevin treatment restores regular Ca^2+^ transients in *tre* hearts.10.7554/eLife.04801.003Figure 1.Efsevin restores rhythmic cardiac contractions in zebrafish tremblor embryos.(**A**) Line scans across the atria of *Tg(myl7:GFP)* embryonic hearts at 48 hpf. Rhythmically alternating systoles and diastoles are recorded from vehicle- (upper left) or efsevin- treated wild type (upper right) and efsevin-treated *tre* (lower right) embryos, while only sporadic unsynchronized contractions are recorded from vehicle-treated *tre* embryos (lower left). (**B**, **C**) Fractional shortening (FS) deduced from the line-scan traces. While cardiac contraction was not observed in *tre*, efsevin-treated wild type and *tre* hearts have similar levels of FS to those observed in control hearts. Ventricular FS of wild type v.s. wild type + efsevin vs tre + efsevin: 39 ± 0.6%, n = 8 vs 39 ± 1%, n = 10 vs 35 ± 3%, n = 6; and Atrial FS: 37 ± 1%, n = 11 vs 35 ± 2%, n = 11 vs 33 ± 2%, n = 15. (**D**) While efsevin restored a heart rate of 46 ± 2 beats per minute (bpm) in *tre* embryos, same treatment does not affect the heart rate in wild type embryos (126 ± 2 bpm in vehicle-treated embryos vs 123 ± 3 bpm in efsevin-treated wild-type embryos). \*\*\*, p \< 0.001 by one-way ANOVA. (**E**) Dose-dependence curve for efsevin. The *tre* embryos were treated with various concentrations of efsevin from 24 hpf and cardiac contractions were analyzed at 48 hpf. (**F**--**H**) Representative time traces of local field potentials for wild type (**F**), *tre* (**G**) and efsevin-treated *tre* (**H**) embryos clearly display periods of regular, irregular, and restored periodic electrical activity. (**I**) In vivo optical maps of Ca^2+^ activation represented by isochronal lines every 33 ms recorded from 36 hpf wild type (left), *tre* (center) and efsevin-treated *tre* (right) embryos.**DOI:** [http://dx.doi.org/10.7554/eLife.04801.003](10.7554/eLife.04801.003)Video 1.The video shows a heart of a wild-type zebrafish embryo at 2 dpf.Robust rhythmic contractions can be observed in atrium and ventricle.**DOI:** [http://dx.doi.org/10.7554/eLife.04801.004](10.7554/eLife.04801.004)10.7554/eLife.04801.004Video 2.This video shows a heart of a *tremblor* embryo at 2 dpf.Embryos of the mutant line *tremblor* display only local, unsynchronized contractions, comparable to cardiac fibrillation.**DOI:** [http://dx.doi.org/10.7554/eLife.04801.005](10.7554/eLife.04801.005)10.7554/eLife.04801.005Video 3.This video shows a heart of a *tremblor* embryo at 2 dpf treated with efsevin.Treatment of *tremblor* embryos with efsevin restores rhythmic contractions with comparable atrial fractional shortening compared to wild-type embryos and approximately 40% of wild-type heart rate.**DOI:** [http://dx.doi.org/10.7554/eLife.04801.006](10.7554/eLife.04801.006)10.7554/eLife.04801.006Video 4.The video shows a heart of a wild-type zebrafish embryo at 2 dpf treated with efsevin.Treatment of wild-type embryos with efsevin did not affect cardiac performance, indicated by robust, rhythmic contractions comparable to untreated wild-type embryos.**DOI:** [http://dx.doi.org/10.7554/eLife.04801.007](10.7554/eLife.04801.007)10.7554/eLife.04801.007Video 5.Heat map of Ca^2+^ transients recorded in 1 day old wild type heart.**DOI:** [http://dx.doi.org/10.7554/eLife.04801.008](10.7554/eLife.04801.008)10.7554/eLife.04801.008Video 6.Heat map of Ca^2+^ transients recorded in 1 day old *tremblor* heart.**DOI:** [http://dx.doi.org/10.7554/eLife.04801.009](10.7554/eLife.04801.009)10.7554/eLife.04801.009Video 7.Heat map of Ca^2+^ transients recorded in 1 day old efsevin treated *tremblor* heart.**DOI:** [http://dx.doi.org/10.7554/eLife.04801.010](10.7554/eLife.04801.010)10.7554/eLife.04801.010

Efsevin suppresses Ca^2+^ overload-induced irregular contraction {#s2-2}
----------------------------------------------------------------

We next examined whether efsevin could suppress aberrant Ca^2+^ homeostasis-induced arrhythmic responses in mammalian cardiomyocytes. Mouse embryonic stem cell-derived cardiomyocytes (mESC-CMs) establish a regular contraction pattern with rhythmic Ca^2+^ transients ([Figure 2A,B,E,F](#fig2){ref-type="fig"}). Mimicking Ca^2+^ overload by increasing extracellular Ca^2+^ levels was sufficient to disrupt normal Ca^2+^ cycling and induce irregular contractions in mESC-CMs ([Figure 2C,E,F](#fig2){ref-type="fig"}). Remarkably, efsevin treatment restored rhythmic Ca^2+^ transients and cardiac contractions in these cells ([Figure 2D--F](#fig2){ref-type="fig"}). Similar effect was observed in human embryonic stem cell-derived cardiomyocytes (hESC-CMs) ([Figure 2G](#fig2){ref-type="fig"}). Together, these findings suggest that efsevin targets a conserved Ca^2+^ regulatory mechanism critical for maintaining rhythmic cardiac contraction in fish, mice and humans.10.7554/eLife.04801.011Figure 2.Efsevin reduces arrhythmogenic events in ES cell-derived cardiomyocytes.(**A**) Line-scan analysis of Ca^2+^ transients in mESC-CMs after 10 days of differentiation. (**B**--**D**) Representative graph of Ca^2+^ transients detected in mESC-CMs (**B**). After treatment with 10 mM Ca^2+^ for 10 min, the EB showed an irregular pattern of Ca^2+^ transients (**C**). Efsevin treatment restores regular Ca^2+^ transients under Ca^2+^ overload conditions in mESC-CMs (**D**). (**E**) Plotted intervals between peaks of Ca^2+^ signals detected in mESC-CMs prior to treatment (control), in 10 mM Ca^2+^~ext~ (Ca^2+^) and in 10 mM Ca^2+^~ext~+10 μM efsevin (Ca^2+^+efsevin). (**F**, **G**) Plotted intervals of contractions detected in EBs prior to treatment (control), in 10 mM Ca^2+^~ext~ (Ca^2+^) and in 10 mM Ca^2+^~ext~ + 10 μM efsevin (Ca^2+^ + efsevin) for mouse ESC-CMs (**F**) and 5 mM Ca^2+^~ext~ (Ca^2+^) and in 5 mM Ca^2+^~ext~ + 5 μM efsevin (Ca^2+^ + efsevin) for human ESC-CMs (**G**). \*\*\*, p \< 0.001 by F-test.**DOI:** [http://dx.doi.org/10.7554/eLife.04801.011](10.7554/eLife.04801.011)

VDAC2 mediates the suppressive effect of efsevin on *tre* {#s2-3}
---------------------------------------------------------

To identify the protein target of efsevin, we generated a N-Boc-protected 2-aminoethoxyethoxyethylamine linker-attached efsevin (efsevin^L^) ([Figure 3A,C](#fig3){ref-type="fig"}). This modified compound retained the activity of efsevin to restore cardiac contractions in *ncx1h* deficient embryos ([Figure 3B,D](#fig3){ref-type="fig"}) and was used to create efsevin-conjugated agarose beads (efsevin^LB^). A 32kD protein species was detected from zebrafish lysate due to its binding ability to efsevin^LB^ and OK-C125^LB^, an active efsevin derivative conjugated to beads, but not to beads capped with ethanolamine alone or beads conjugated with an inactive efsevin analog (OK-C19^LB^) ([Figure 3A--E](#fig3){ref-type="fig"}). Furthermore, preincubation of zebrafish lysate with excess efsevin prevented the 32kD protein from binding to efsevin^LB^ or OK-C125^LB^ ([Figure 3E](#fig3){ref-type="fig"}). Mass spectrometry analysis revealed that this 32kD band represents a zebrafish homologue of the mitochondrial voltage-dependent anion channel 2 (VDAC2) ([Figure 3F](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}).10.7554/eLife.04801.012Figure 3.VDAC2 is a protein target of efsevin.(**A**) Structures of efsevin and two derivatives, OK-C125 and OK-C19. (**B**) Efsevin and OK-C125 restored rhythmic contractions in the majority of *tremblor* embryos, whereas OK-C19 failed to rescue the *tremblor* phenotype. (**C**) Structures of linker-attached compounds (indicated by superscript L). (**D**) Compounds efsevin^L^ and OK-C125^L^ retained their ability to restore rhythmic contractions in NCX1hMO injected embryos, while the inactive derivative OK-C19^L^ was still unable to induce rhythmic contraction. (**E**) Affinity agarose beads covalently linked with efsevin (efsevin^LB^) or OK-C125 (OK-C125^LB^) pulled down 2 protein species from zebrafish embryonic lysate, whereof one, the 32 kD upper band, was sensitive to competition with a 100-fold excess free efsevin^L^. The 32 kD band was not detected in proteins eluted from beads capped with ethanolamine alone (beads^C^) or beads linked to OK-C19 (OK-C19^LB^). Arrowheads point to the 32kD bands. (**F**) Mass Spectrometry identifies the 32kD band as VDAC2. Peptides identified by mass spectrometry (underlined) account for 30% of the total sequence.**DOI:** [http://dx.doi.org/10.7554/eLife.04801.012](10.7554/eLife.04801.012)10.7554/eLife.04801.013Figure 3---figure supplement 1.Mass Spectometry identifies VDAC2 as the target of efsevin.Image shows an example of the identification of VDAC2 peptide. Diagnostic b- and y-series ions are shown in red and blue, respectively.**DOI:** [http://dx.doi.org/10.7554/eLife.04801.013](10.7554/eLife.04801.013)

VDAC2 is expressed in the developing zebrafish heart ([Figure 4A](#fig4){ref-type="fig"}), making it a good candidate for mediating efsevin's effect on cardiac Ca^2+^ handling. To examine this possibility, we injected in vitro synthesized VDAC2 RNA into *tre* embryos and found that the majority of these embryos had coordinated cardiac contractions similar to those subjected to efsevin treatment ([Figure 4B](#fig4){ref-type="fig"}, [Videos 8--11](#video8 video9 video10 video11){ref-type="other"}). In addition, we generated *myl7:VDAC2* transgenic fish in which VDAC2 expression can be induced in the heart by tebufenozide (TBF) ([Figure 4C](#fig4){ref-type="fig"}). Knocking down NCX1h in *myl7:VDAC2* embryos results in chaotic cardiac movement similar to *tre*. Like efsevin treatment, induction of VDAC2 expression by TBF treatment restored coordinated and rhythmic contractions in *myl7:VDAC2;NCX1h MO* hearts ([Figure 4D](#fig4){ref-type="fig"}, [Videos 12,13](#video12 video13){ref-type="other"}). Conversely, knocking down VDAC2 in *tre* hearts attenuated the suppressive effect of efsevin ([Figure 4E](#fig4){ref-type="fig"}, [Videos 14--16](#video14 video15 video16){ref-type="other"}). Furthermore, we generated VDAC2 null embryos by the Zinc Finger Nuclease gene targeting approach ([Figure 4G](#fig4){ref-type="fig"}). Similar to that observed in morpholino knockdown embryos, homozygous *VDAC2*^*LA2256*^ embryos do not exhibit noticeable morphological defects, but the suppressive effect of efsevin was attenuated in homozygous *VDAC2^LA2256^; NCX1MO* embryos ([Figure 4F](#fig4){ref-type="fig"}). These findings demonstrate that VDAC2 is a major mediator for efsevin's effect on *ncx1h* deficient hearts.10.7554/eLife.04801.014Figure 4.VDAC2 restores rhythmic cardiac contractions in *tre*.(**A**) In situ hybridization analysis showed that VDAC2 is expressed in embryonic hearts at 36 hpf (upper image) and 48 hpf (lower image). (**B**) Injection of 25 pg in vitro synthesized VDAC2 mRNA restored cardiac contractions in 52.9 ± 12.1% (n = 78) of 1-day-old *tre* embryos, compared to 21.8 ± 5.1% in uninjected siblings (n = 111). (**C**) Schematic diagram of *myl7:VDAC2* construct (top). In situ hybridization analysis showed that TBF treatment induces VDAC2 expression in the heart (lower panel). (**D**) While only ∼20% of *myl7:VDAC2;NCX1hMO* embryos have coordinated contractions (n = 116), 52.3 ± 2.4% of these embryos established persistent, rhythmic contractions after TBF induction of VDAC2 (n = 154). (**E**) On average, 71.2 ± 8.8% efsevin treated embryos have coordinated cardiac contractions (n = 131). Morpholino antisense oligonucleotide knockdown of VDAC2 (MO^VDAC2^) attenuates the ability of efsevin to suppress cardiac fibrillation in *tre* embryos (45.3 ± 7.4% embryos with coordinated contractions, n = 94). (**F**) Efsevin treatment restores coordinated cardiac contractions in 76.2 ± 8.7% NCX1MO embryos, only 54.1 ± 3.6% VDAC2^zfn/zfn^;NCX1MO embryos have coordinated contractions (n = 250). (**G**) Diagram of Zinc finger target sites. *VDAC2*^*zfn/zfn*^ carries a 34 bp deletion in exon 3 which results in a premature stop codon (red asterisk). In situ hybridization analysis showing loss of VDAC2 transcripts in *VDAC2*^*zfn/zfn*^ embryos. White arrowheads point to the developing heart.**DOI:** [http://dx.doi.org/10.7554/eLife.04801.014](10.7554/eLife.04801.014)Video 8.This video shows a heart of a wild-type zebrafish embryo at 1 dpf.Robust rhythmic contractions can be observed in atrium and ventricle.**DOI:** [http://dx.doi.org/10.7554/eLife.04801.015](10.7554/eLife.04801.015)10.7554/eLife.04801.015Video 9.This video shows a heart of a wild-type zebrafish embryo injected with zebrafish VDAC2 mRNA at 1 dpf.Robust rhythmic contractions can be observed in atrium and ventricle.**DOI:** [http://dx.doi.org/10.7554/eLife.04801.016](10.7554/eLife.04801.016)10.7554/eLife.04801.016Video 10.This video shows a heart of a *tremblor* embryo at 1 dpf.*Tremblor* embryos display only local, unsynchronized contractions, comparable to cardiac fibrillation.**DOI:** [http://dx.doi.org/10.7554/eLife.04801.017](10.7554/eLife.04801.017)10.7554/eLife.04801.017Video 11.This video shows a heart of a *tremblor* embryo injected with zebrafish VDAC2 mRNA at 1 dpf.Overexpression of zebrafish VDAC2 mRNA restores rhythmic contractions in *tremblor* embryos.**DOI:** [http://dx.doi.org/10.7554/eLife.04801.018](10.7554/eLife.04801.018)10.7554/eLife.04801.018Video 12.This video shows a heart of a 2 dpf Tg-VDAC2 embryo injected with a morpholino targeting NCX1h.Morpholino knock-down of NCX1h results in a fibrillating heart.**DOI:** [http://dx.doi.org/10.7554/eLife.04801.019](10.7554/eLife.04801.019)10.7554/eLife.04801.019Video 13.This video shows a heart of a 2 dpf NCX1h morphant in the Tg-VDAC2 genetic background.TBF treatment induces VDAC2 expression and restores coordinated cardiac contractions.**DOI:** [http://dx.doi.org/10.7554/eLife.04801.020](10.7554/eLife.04801.020)10.7554/eLife.04801.020Video 14.This video shows a heart of a 2 dpf wild type zebrafish embryo injected with a morpholino targeting VDAC2.Morpholino knockdown of VDAC2 did not have obvious effects on cardiac performance.**DOI:** [http://dx.doi.org/10.7554/eLife.04801.021](10.7554/eLife.04801.021)10.7554/eLife.04801.021Video 15.This video shows a heart of a 2 dpf *tremblor* mutant embryo injected with a morpholino targeting VDAC2.**DOI:** [http://dx.doi.org/10.7554/eLife.04801.022](10.7554/eLife.04801.022)10.7554/eLife.04801.022Video 16.This video shows a heart of a 2 dpf *tremblor* mutant embryo injected with a morpholino targeting VDAC2.Efsevin treatment cannot restore coordinated cardiac contractions in the absence of VDAC2.**DOI:** [http://dx.doi.org/10.7554/eLife.04801.023](10.7554/eLife.04801.023)10.7554/eLife.04801.023

VDAC2-dependent effect of efsevin on mitochondrial Ca^2+^ uptake {#s2-4}
----------------------------------------------------------------

VDAC is an abundant channel located on the outer mitochondrial membrane serving as a primary passageway for metabolites and ions ([Figure 5A](#fig5){ref-type="fig"}) ([@bib44]; [@bib2]; [@bib53]). At its close state, VDAC favours Ca^2+^ flux ([@bib56]). To examine whether efsevin would modulate mitochondrial Ca^2+^ uptake via VDAC2, we transfected HeLa cells with VDAC2. We noted increased mitochondrial Ca^2+^ uptake in permeabilized VDAC2 transfected and efsevin-treated cells after the addition of Ca^2+^ and the combined treatment further enhanced mitochondrial Ca^2+^ levels ([Figure 5B](#fig5){ref-type="fig"}).10.7554/eLife.04801.024Figure 5.Efsevin enhances mitochondrial Ca^2+^ uptake.(**A**) HeLa cells were transfected with a flag-tagged zebrafish VDAC2 (VDAC2^flag^), immunostained against the flag epitope and counterstained for mitochondria with MitoTracker Orange and for nuclei with DAPI. (**B**) Representative traces of mitochondrial matrix \[Ca^2+^\] (\[Ca^2+^\]~m~) detected by Rhod2. Arrows denote the addition of Ca^2+^. Mitochondrial Ca^2+^ uptake was assessed when VDAC2 was overexpressed (left), cells were treated with 1 µM efsevin (middle) and combination of both at suboptimal doses (right). Control-traces with ruthenium red (RuRed) show mitochondrial specificity of the signal. (**C**) Representative traces of cytosolic \[Ca^2+^\] (\[Ca^2+^\]~c~) changes upon the application of 7.5 µM IP~3~ in the presence (+) or absence (−) of RuRed. Mitochondrial Ca^2+^ uptake was assessed by the difference of the -- and + RuRed conditions normalized to the total release (n = 4; mean ± SE). (**D**) MEFs overexpressing zebrafish VDAC2 (polycistronic with mCherry) were stimulated with 1 μM ATP in a nominally Ca^2+^ free buffer. Changes in \[Ca^2+^\]~c~ and \[Ca^2+^\]~m~ were imaged using fura2 and mitochondria-targeted inverse pericam, respectively. Black and gray traces show the \[Ca^2+^\]~c~ (in nM) and \[Ca^2+^\]~m~ (F~0~/F mtpericam) time courses in the absence (left) or present (right) of efsevin. (**E**) Bar charts: Cell population averages for the peak \[Ca^2+^\]~c~ (left), the corresponding \[Ca^2+^\]~m~ (middle), and the coupling time (time interval between the maximal \[Ca^2+^\]~c~ and \[Ca^2+^\]~m~ responses) in the presence (black, n = 24) or absence (gray, n = 28) of efsevin.**DOI:** [http://dx.doi.org/10.7554/eLife.04801.024](10.7554/eLife.04801.024)10.7554/eLife.04801.025Figure 5---figure supplement 1.Local Ca^2+^ delivery between IP3 receptors and VDAC2.V1V3DKO MEFs were stimulated with 100 μM ATP (left) or 2 μM thapsigargan (Tg) (right). Changes in \[Ca^2+^\]~c~ and \[Ca^2+^\]~m~ were imaged using fura2 and mitochondria targeted inverse pericam, respectively. Representative traces obtained in three cells are shown.**DOI:** [http://dx.doi.org/10.7554/eLife.04801.025](10.7554/eLife.04801.025)

Mitochondria are located in close proximity to Ca^2+^ release sites of the ER/SR and an extensive crosstalk between the two organelles exists ([@bib26]; [@bib30]; [@bib8]; [@bib20]; [@bib33]). We examined whether Ca^2+^ released from intracellular stores could be locally transported into mitochondria through VDAC2 in VDAC1/VDAC3 double knockout (V1/V3DKO) MEFs where VDAC2 is the only VDAC isoform being expressed ([@bib48]). While treatments with ATP, an IP3-linked agonist, and thapsigargin, a SERCA inhibitor, stimulated similar global cytoplasmic \[Ca^2+^\] elevation in intact cells, only ATP induced a rapid mitochondrial matrix \[Ca^2+^\] rise ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). This finding is consistent with observations obtained in other cell types ([@bib46]; [@bib29]) and suggests that Ca^2+^ was locally transferred from IP3 receptors to mitochondria through VDAC2 at the close ER-mitochondrial associations. We next investigated whether this process could be modulated by efsevin. In permeabilized V1/V3DKO MEFs, treatment with efsevin increased the amount of Ca^2+^ transferred into mitochondria during IP~3~-induced Ca^2+^ release ([Figure 5C](#fig5){ref-type="fig"}). Also, in intact V1/V3 DKO MEFs, efsevin accelerated the transfer of Ca^2+^ released from intracellular stores into mitochondria during stimulation with ATP ([Figure 5D,E](#fig5){ref-type="fig"}).

Efsevin modulates Ca^2+^ sparks and suppresses erratic Ca^2+^ waves in cardiomyocytes {#s2-5}
-------------------------------------------------------------------------------------

We next examined the effect of efsevin on cytosolic Ca^2+^ signals in isolated adult murine cardiomyocytes. We found that efsevin treatment induced faster inactivation kinetics without affecting the amplitude or time to peak of paced Ca^2+^ transients ([Figure 6A](#fig6){ref-type="fig"}). Similarly, efsevin treatment did not significantly alter the frequency, amplitude or Ca^2+^ release flux of spontaneous Ca^2+^ sparks, local Ca^2+^ release events, but accelerated the decay phase resulting in sparks with a shorter duration and a narrower width ([Figure 6B](#fig6){ref-type="fig"}). These results indicate that by activating mitochondrial Ca^2+^ uptake, efsevin accelerates Ca^2+^ removal from the cytosol in cardiomyocytes and thereby restricts local cytosolic Ca^2+^ sparks to a narrower domain for a shorter period of time without affecting SR Ca^2+^ load or RyR Ca^2+^ release. Under conditions of Ca^2+^ overload, single Ca^2+^ sparks can trigger opening of neighbouring Ca^2+^ release units and thus induce the formation of erratic Ca^2+^ waves ([Figure 6C](#fig6){ref-type="fig"}). Efsevin treatment significantly reduced the number of propagating Ca^2+^ waves in a dosage-dependent manner ([Figure 6C,D](#fig6){ref-type="fig"}), demonstrating a potent suppressive effect of efsevin on the propagation of Ca^2+^ overload-induced Ca^2+^ waves and suggesting that efsevin could serve as a pharmacological tool to manipulate local Ca^2+^ signals.10.7554/eLife.04801.026Figure 6.Effects of efsevin on isolated cardiomyocytes.(**A**) Electrically paced Ca^2+^ transients at 0.5 Hz (top). Normalized quantification of Ca^2+^ transient parameters reveals no difference for transient amplitude (efsevin-treated at 98.6 ± 4.5% of vehicle-treated) and time to peak (95 ± 3.9%), but a significant decrease for the rate of decay (82.8 ± 4% of vehicle- for efsevin-treated) (lower panel). (**B**) Representation of typical Ca^2+^ sparks of vehicle- and efsevin treated cardiomyocytes (top). No differences were observed for spark frequency (101.1 ± 7.7% for efsevin- compared to vehicle-treated), maximum spark amplitude (101.6 ± 2.5%) and Ca^2+^ release flux (98.7 ± 2.8%). In contrast, the decay phase of the single spark was significantly faster in efsevin treated cells (82.5 ± 2.1% of vehicle-treated). Consequently, total duration of the spark was reduced to 85.7 ± 2% and the total width was reduced to 89.5 ± 1.4% of vehicle-treated cells. \*, p \< 0.05; \*\*\*, p \< 0.001. (**C**) Increasing concentrations of extracellular Ca^2+^ induced a higher frequency of spontaneous propagating Ca^2+^ waves in isolated adult murine ventricular cardiomyocytes. Efsevin treatment reduced Ca^2+^ waves in a dose-dependent manner. (**D**) Quantitative analysis of spontaneous Ca^2+^ waves spanning more than half of the entire cell. Addition of 1 µM efsevin reduced Ca^2+^ waves to approximately half. Increasing the concentration of efsevin to 10 µM further reduced the number of spontaneous Ca^2+^ waves and 25 µM efsevin almost entirely blocked the formation of Ca^2+^ waves.**DOI:** [http://dx.doi.org/10.7554/eLife.04801.026](10.7554/eLife.04801.026)

Mitochondrial Ca^2+^ uptake modulates embryonic cardiac rhythmicity {#s2-6}
-------------------------------------------------------------------

We hypothesize that efsevin treatment/VDAC2 overexpression suppresses aberrant Ca^2+^ handling-associated arrhythmic cardiac contractions by buffering excess Ca^2+^ into mitochondria. This hypothesis predicts that activating other mitochondrial Ca^2+^ uptake molecules would likewise restore coordinated contractions in *tre*. To test this model, we cloned zebrafish MCU and MICU1, an inner mitochondrial membrane Ca^2+^ transporter and its regulator ([@bib42]; [@bib3]; [@bib18]; [@bib38]; [@bib15]). In situ hybridization showed that MCU and MICU1 were expressed in the developing zebrafish heart ([Figure 7A](#fig7){ref-type="fig"}) and their expression levels were comparable between the wild type and *tre* hearts ([Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}). Overexpression of MCU restored coordinated contractions in *tre*, akin to what was observed with VDAC2 ([Figure 7B](#fig7){ref-type="fig"}). In addition, *tre* embryos injected with suboptimal concentrations of MCU or VDAC2 had a fibrillating heart, but embryos receiving both VDAC2 and MCU at the suboptimal concentration manifested coordinated contractions ([Figure 7C](#fig7){ref-type="fig"}), demonstrating a synergistic effect of these proteins. Furthermore, overexpression of MCU failed to suppress the *tre* phenotype in the absence of VDAC2 activity and VDAC2 could not restore coordinated contractions in *tre* without functional MCU ([Figure 7B,D](#fig7){ref-type="fig"}). Similar results were observed by manipulating MICU1 activity ([Figure 7E,F](#fig7){ref-type="fig"}). Together, these findings indicate that mitochondrial Ca^2+^ uptake mechanisms on outer and inner mitochondrial membranes act cooperatively to regulate cardiac rhythmicity.10.7554/eLife.04801.027Figure 7.Mitochondria regulate cardiac rhythmicity through a VDAC2-dependent mechanism.(**A**) MCU and MICU1 are expressed in the developing zebrafish hearts (arrowhead). (**B**) Overexpression of MCU is sufficient to restore coordinated cardiac contractions in *tre* embryos (47.1 ± 1.6% embryos, n = 112 as opposed to 18.3 ± 5.3% of uninjected siblings, n = 64) while this effect is significantly attenuated when co-injected with morpholino antisense oligonucleotide targeted to VDAC2 (27.1 ± 1.9% embryos, n = 135). (**C**) Suboptimal overexpression of MCU (MCU^S^) and VDAC2 (VDAC2^S^) in combination is able to suppress cardiac fibrillation in *tre* embryos (42.9 ± 2.6% embryos, n = 129). (**D**) The ability of VDAC2 to restore rhythmic contractions in *tre* embryos (48.5 ± 3.5% embryos, n = 111) is significantly attenuated when MCU is knocked down by antisense oligonucleotide (MO^MCU^) (25.6 ± 2.4% embryos, n = 115). (**E**) Overexpression of MICU1 is sufficient to restore rhythmic cardiac contractions in *tre* embryos (49.3 ± 3.4% embryos, n = 127 compared to 16.8 ± 1.4% of uninjected siblings, n = 150). This effect is abrogated by VDAC2 knockdown (MO^VDAC2^, 25.3 ± 5.5% embryos, n = 97). (**F**) Suboptimal overexpression of MICU1 (MICU1^S^) and VDAC2 (VDAC2^S^) in combination is able to restore rhythmic cardiac contractions in *tre* embryos (48.6 ± 6.0%, n = 106). Error bars represent s.d.; \*p \< 0.05; \*\*\*p \< 0.001.**DOI:** [http://dx.doi.org/10.7554/eLife.04801.027](10.7554/eLife.04801.027)10.7554/eLife.04801.028Figure 7---figure supplement 1.Expression of MCU, MICU1 and VDAC2.In situ hybridization analysis shows that the expression levels of MCU, MICU1 and VDAC2 are comparable between wild type and *tre* embryos with and without efsevin treatment.**DOI:** [http://dx.doi.org/10.7554/eLife.04801.028](10.7554/eLife.04801.028)

Conclusion {#s2-7}
----------

In summary, we conducted a chemical suppressor screen in zebrafish to dissect the regulatory network critical for maintaining rhythmic cardiac contractions and to identify mechanisms underlying aberrant Ca^2+^ handling-induced cardiac dysfunction. We show that activation of VDAC2 through overexpression or efsevin treatment potently restores rhythmic contractions in NCX1h deficient zebrafish hearts and effectively suppresses Ca^2+^ overload-induced arrhythmogenic Ca^2+^ events and irregular contractions in mouse and human cardiomyocytes. We provide evidence that potentiating VDAC2 activity enhances mitochondrial Ca^2+^ uptake, accelerates Ca^2+^ transfer from intracellular stores into mitochondria and spatially and temporally restricts single Ca^2+^ sparks in cardiomyocytes. The crucial role of mitochondria in the regulation of cardiac rhythmicity is further supported by the findings that VDAC2 functions in concert with MCU; these genes have a strong synergistic effect on suppressing cardiac fibrillation and loss of function of either gene abrogates the rescue effect of the other in *tre*.

The regulatory roles of mitochondrial Ca^2+^ in cardiac metabolism, cell survival and fate have been studied extensively ([@bib8]; [@bib20]; [@bib19]; [@bib31]; [@bib33]; [@bib36]). Our study provides genetic and physiologic evidence supporting an additional role for mitochondria in regulating cardiac rhythmicity and reveals VDAC2 as a modulator of Ca^2+^ handling in cardiomyocytes. Our findings, together with recent reports of the physical interaction between VDAC2 and RyR2 ([@bib40]) and the close proximity of outer and inner mitochondrial membranes at the contact sites between the mitochondria and the SR ([@bib27]), suggest an intriguing model. We propose that mitochondria facilitate an efficient clearance mechanism in the Ca^2+^ microdomain, which modulates Ca^2+^ handling without affecting global Ca^2+^ signals in cardiomyocytes. In this model, VDAC facilitates mitochondrial Ca^2+^ uptake via MCU complex and thereby controls the duration and the diffusion of cytosolic Ca^2+^ near the Ca^2+^ release sites to ensure rhythmic cardiac contractions. This model is consistent with our observation that efsevin treatment induces faster inactivation kinetics of cytosolic Ca^2+^ transients without affecting the amplitude or the time to peak in cardiomyocytes and the reports that blocking mitochondrial Ca^2+^ uptake has little impact on cytosolic Ca^2+^ transients ([@bib37]; [@bib32]). Further support for this model comes from the observation of the Ca^2+^ peaks on the OMM ([@bib21]) and the finding that downregulating VDAC2 extends Ca^2+^ sparks ([@bib55]; [@bib40]) and that blocking mitochondrial Ca^2+^ uptake by Ru360 leads to an increased number of spontaneous propagating Ca^2+^ waves ([@bib51]). Future studies on the kinetics of VDAC2-dependent mitochondrial Ca^2+^ uptake and exploring potential regulatory molecules for VDAC2 activity will provide insights into how the crosstalk between SR and mitochondria contributes to Ca^2+^ handling and cardiac rhythmicity.

Aberrant Ca^2+^ handling is associated with many cardiac dysfunctions including arrhythmia. Establishing animal models to study molecular mechanisms and develop new therapeutic strategies are therefore major preclinical needs. Our chemical suppressor screen identified a potent effect of efsevin and its biological target VDAC2 on manipulating cardiac Ca^2+^ handling and restoring regular cardiac contractions in fish and mouse and human cardiomyocytes. This success indicates that fundamental mechanisms regulating cardiac function are conserved among vertebrates despite the existence of species-specific features and suggests a new paradigm of using zebrafish cardiac disease models for the dissection of critical genetic pathways and the discovery of new therapeutic approaches. Future studies examining the effects of efsevin on other arrhythmia models would further elucidate the potential for efsevin as a pharmacological tool to treat cardiac arrhythmia associated with aberrant Ca^2+^ handling.

Materials and methods {#s3}
=====================

Zebrafish husbandry and transgenic lines {#s3-1}
----------------------------------------

Zebrafish of the mutant line *tremblor* (*tre*^*tc318*^) were maintained and bred as described previously ([@bib35]). Transgenic lines, *myl7:gCaMP4.1*^*LA2124*^ and *myl7:VDAC2*^*LA2309*^ were created using the Tol2kit ([@bib23]; [@bib34]; [@bib52]). The *VDAC2*^*LA2256*^ was created using the zinc finger array OZ523 and OZ524 generated by the zebrafish Zinc Finger Consortium ([@bib24], [@bib25]).

Molecular Biology {#s3-2}
-----------------

Full length VDAC2 cDNA was purchased from Open Biosystems (Huntsville, AL) and cloned into pCS2+ or pCS2+3XFLAG. Full length cDNA fragments of zebrafish MCU (Accession number: JX424822) and MICU1 (JX42823) were amplified from 2 dpf embryos and cloned into pCS2+. For mRNA synthesis, plasmids were linearized and mRNA was synthesized using the SP6 mMESSAGE mMachine kit according to the manufacturers manual (Ambion, Austin, TX.).

Zebrafish injections {#s3-3}
--------------------

VDAC2 mRNA and morpholino antisense oligos (5′-GGGAACGGCCATTTTATCTGTTAAA-3′) (Genetools, Philomath, OR) were injected into one-cell stage embryos collected from crosses of *tre*^*tc318*^ heterozygotes. Cardiac performance was analyzed by visual inspection on 1 dpf. The *tre* mutant embryos were identified either by observing the fibrillation phenotype at 2--3 dpf or by genotyping as previously described ([@bib35]).

Chemical screen {#s3-4}
---------------

Chemicals from a synthetic library ([@bib9]; [@bib13]; [@bib14]) and from Biomol International LP (Farmingdale, NY) were screened for their ability to partially or completely restore persistent heartbeat in *tre* embryos. 12 embryos collected from crosses of *tre*^*tc318*^ heterozygotes were raised in the presence of individual compounds at a concentration of 10 µM from 4 hpf ([@bib13]). Cardiac function was analyzed by visual inspection at 1 and 2 dpf. The hearts of *tre*^*tc318*^ embryos manifest a chaotic movement resembling cardiac fibrillation with intermittent contractions in rare occasion ([@bib22]; [@bib35]). Compounds that elicit persistent coordinated cardiac contractions were validated on large number of *tre* mutant embryos and NCX1h morphants (\>500 embryos).

Zebrafish cardiac imaging {#s3-5}
-------------------------

Videos of GFP-labelled *myl7:GFP* hearts were taken at 30 frames per second. Line-scan analysis was performed along a line through the atria or the ventricles of these hearts ([@bib41]). Fraction of shortening was deduced from the ratio of diastolic and systolic width and heart rate was determined by beats per minute. Cardiac parameters were analyzed in *tremblor*^*tc318*^ and *VDAC2*^*LA2256*^ at 2 dpf.

Zebrafish optical mapping {#s3-6}
-------------------------

36 hpf *myl7:gCaMP4.1* embryos were imaged at a frame rate of 30 ms/frame. Electromechanical isolation was achieved by tnnt2MO ([@bib39]). The fluorescence intensity of each pixel in a 2D map was normalize to generate heat maps and isochronal lines at 33 ms intervals were obtained by identifying the maximal spatial gradient for a given time point ([@bib11]).

Mouse and human embryonic stem cells {#s3-7}
------------------------------------

The mouse E14Tg2a ESC and human H9 ESC line were cultured and differentiated as previously described ([@bib5]; [@bib1]). At day 10 of differentiation, beating mouse EBs were exposed to external solution containing 10 mM CaCl~2~ for 10 min before DMSO or efsevin (10 μM) treatment. Human EBs were differentiated for 15 days and treated with 5 mM CaCl~2~ for 10 min before DMSO or efsevin (5 μM) treatment. Images of beating EBs were acquired at a rate of 30 frames/s and analyzed by motion-detection software. For calcium recording, the EBs were loaded with 10 μM fluo-4 AM in culture media for 30 min at 37°C. Line-scan analysis was performed and fluorescent signals were acquired by a Zeiss LSM510 confocal microscope.

Microelectrode array measurements {#s3-8}
---------------------------------

2-day-old wild type, *tre,* and efsevin-treated *tre* embryos were placed on uncoated, microelectrode arrays (MEAs) containing 120 integrated TiN electrodes (30 μm diameter, 200 μm interelectrode spacing). Local field potentials (LFPs) at each electrode were collected for three trials per embryo type over a period of three minutes at a sampling rate of 1 kHz using the MEA2100-HS120 system (Multichannel Systems, Reutiligen, Germany). Raw data was low-pass filtered at a cutoff frequency of 10 Hz using a third-order Butterworth filter. Data analysis was carried out using the MC_DataTool (Multichannel Systems) and Matlab (MathWorks).

Ca^2+^ imaging {#s3-9}
--------------

Murine ventricular cardiomyocytes were isolated as previously described ([@bib45]). Cells were loaded with 5 µM fluo-4 AM in external solution containing: 138.2 mM NaCl, 4.6 mM KCl, 1.2 mM MgCl, 15 mM glucose, 20 mM HEPES for 1 hr and imaged in external solution supplemented with 2, 5 or 10 mM CaCl~2~. For the recording of Ca^2+^ sparks and transients, the external solution contained 2 mM CaCl~2~. For Ca^2+^ transients, cells were field stimulated at 0.5 Hz with a 5 ms pulse at a voltage of 20% above contraction threshold. For all measurements, efsevin was added 2 hr prior to the actual experiment. Images were recorded on a Zeiss LSM 5 Pascal confocal microscope. Data analysis was carried out using the Zeiss LSM Image Browser and ImageJ with the SparkMaster plugin ([@bib43]). Cells were visually inspected prior to and after each recording. Only those recordings from healthy looking cells with distinct borders, uniform striations and no membrane blebs or granularity were included in the analysis.

Biochemistry {#s3-10}
------------

For pull down assays mono-N-Boc protected 2,2\'-(ethylenedioxy)bis(ethylamine) was attached to the carboxylic ester of efsevin and its derivatives through the amide bond. After removal of the Boc group using TFA, the primary amine was coupled to the carboxylic acid of Affi-Gel 10 Gel (Biorad, Hercules, CA). 2-day-old zebrafish embryos were deyolked by centrifugation before being lysed with Rubinfeld\'s lysis buffer ([@bib50]). The lysate was precleaned by incubation with Affi-Gel 10 Gel to eliminate non-specific binding. Precleaned lysate was incubated with affinity beads overnight. Proteins were eluted from the affinity beads and separated on SDS-PAGE. Protein bands of interest were excised. Gel plugs were dehydrated in acetonitrile (ACN) and dried completely in a Speedvac. Samples were reduced and alkylated with 10 mM dithiotreitol and 10 mM TCEP solution in 50 mM NH~4~HCO~3~ (30 min at 56°C) and 100 mM iodoacetamide (45 min in dark), respectively. Gel plugs were washed with 50 mM NH~4~HCO~3~, dehydrated with ACN, and dried down in a Speedvac. Gel pieces were then swollen in digestion buffer containing 50 mM NH~4~HCO~3~, and 20.0 ng/μl of chymotrypsin (25°C, overnight). Peptides were extracted with 0.1% TFA in 50% ACN solution, dried down and resuspended in LC buffer A (0.1% formic acid, 2% ACN).

Mass spectrometry analyses and database searching {#s3-11}
-------------------------------------------------

Extracted peptides were analyzed by nano-flow LC/MS/MS on a Thermo Orbitrap with dedicated Eksigent nanopump using a reversed phase column (New Objective, Woburn, MA). The flow rate was 200 nl/min for separation: mobile phase A contained 0.1% formic acid, 2% ACN in water, and mobile phase B contained 0.1% formic acid, 20% water in ACN. The gradient used for analyses was linear from 5% B to 50% B over 60 min, then to 95% B over 15 min, and finally keeping constant 95% B for 10 min. Spectra were acquired in data-dependent mode with dynamic exclusion where the instrument selects the top six most abundant ions in the parent spectra for fragmentation. Data were searched against the *Danio rerio* IPI database v3.45 using the SEQUEST algorithm in the BioWorks software program version 3.3.1 SP1. All spectra used for identification had deltaCN\>0.1 and met the following Xcorr criteria: \>2 (+1), \>3 (+2), \>4 (+3), and \>5 (+4). Searches required full cleavage with the enzyme, [\<]{.ul}4 missed cleavages and were performed with the differential modifications of carbamidomethylation on cysteine and methionine oxidation.

In situ hybridization {#s3-12}
---------------------

In situ hybridization was performed as previously described ([@bib10]). DIG-labeled RNA probe was synthesized using the DIG RNA labeling kit (Roche, Indianapolis, IN).

Immunostaining {#s3-13}
--------------

HeLa cells were transfected with a C-terminally flag-tagged zebrafish VDAC1 or VDAC2 in plasmid pCS2+ using Lipofectamine 2000 (Invitrogen). After staining with MitoTracker Orange (Invitrogen) cells were fixed in 3.7% formaldehyde and permeabilized with acetone. Immunostaining was performed using primary antibody ANTI-FLAG M2 (Sigma Aldrich, St. Luis, MO) at 1:100 and secondary antibody Anti-Mouse IgG1-FITC (Southern Biotechnology Associates, Birmingham, AL) at 1:200. Cells were mounted and counterstained using Vectashield Hard Set with DAPI (Vector Laboratories, UK).

Mitochondria Ca^2+^ uptake assay in HeLa cells {#s3-14}
----------------------------------------------

HeLa cells were transfected with zebrafish VDAC2 using Lipofectamine 2000 (Invitrogen, Carlsbad, CA). 36 hrs after transfection, cells were loaded with 5 µM Rhod2-AM (Invitrogen), a Ca^2+^ indicator preferentially localized in mitochondria, for 1 hr at 15°C followed by a 30 min de-esterification period at 37°C. Subsequently, cells were permeabilized with 100 µM digitonin for 1 min at room temperature. Fluorescence changes in Rhod2 (ex: 544 nm, em: 590 nm) immediately after the addition of Ca^2+^ (final free Ca^2+^ concentration is calculated to be approximately 10 µM using WEBMAXC at [http://web.stanford.edu/∼cpatton/webmaxcS.htm](http://web.stanford.edu/%7Ecpatton/webmaxcS.htm)) were monitored in internal buffer (5 mM K-EGTA, 20 mM HEPES, 100 mM K-aspartate, 40 mM KCl, 1 mM MgCl~2~, 2 mM maleic acid, 2 mM glutamic acid, 5 mM pyruvic acid, 0.5 mM KH~2~PO~4~, 5 mM MgATP, pH adjusted to 7.2 with Trizma base) using a FLUOSTAR plate reader (BMG Labtech, Germany).

Mitochondria Ca^2+^ uptake assay in VDAC1/VDAC3 double knockout (V1/V3 DKO) MEFs {#s3-15}
--------------------------------------------------------------------------------

V1/V3 DKO MEFs were cultured as previously described ([@bib48]). Efsevin-treated (15 μM for 30 min) or mock-treated MEFs were used for measurements of \[Ca^2+^\]~c~ in suspensions of permeabilized cells or imaging of \[Ca^2+^\]~m~ simultaneously with \[Ca^2+^\]~c~ in intact single cells. Permeabilization of the plasma membrane was performed by digitonin (40 μM/ml). Changes in \[Ca^2+^\] in the cytoplasmic buffer upon IP~3~ (7.5 μM) addition in the presence or absence of ruthenium red (3 μM) was measured by fura2 in a fluorometer ([@bib16]; [@bib49]). To avoid endoplasmic reticulum Ca^2+^ uptake 2 μM thapsigargin was added before IP~3~. For imaging of \[Ca^2+^\]~m~ and \[Ca^2+^\]~c~, MEFs were co-transfected with plasmids encoding polycistronic zebrafish VDAC2 with mCherry and mitochondria-targeted inverse pericam for 40 hr. Cells were sorted to enrich the transfected cells and attached to glass coverslips. In the final 10 min, of the efsevin or mock-treatment, the cells were also loaded with fura2AM (2.5 μM) and subsequently transferred to the microscope stage. Stimulation with 1 μM ATP was carried out in a norminally Ca^2+^ free buffer. Changes in \[Ca^2+^\]~c~ and \[Ca^2+^\]~m~ were imaged using fura2 (ratio of ex:340 nm--380 nm) and mitochondria-targeted inverse pericam (ex: 495 nm), respectively ([@bib17]).

Statistics {#s3-16}
----------

All values are expressed as mean ± SEM, unless otherwise specified. Significance values are calculated by unpaired student\'s t-test unless noted otherwise.
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Thank you for sending your work entitled "Activation of VDAC2 regulates mitochondrial Ca2+ uptake and cardiac rhythmicity" for consideration at *eLife*. Your article has been favorably evaluated by Vivek Malhotra (Senior editor), a Reviewing editor, and 2 reviewers.

The following individuals responsible for the peer review of your submission have agreed to reveal their identity: Jodi Nunnari (Reviewing editor); Rosario Rizzuto (peer reviewer 1). Reviewer 2 remains anonymous.

The Reviewing editor and the reviewers discussed their comments before we reached this decision, and the Reviewing editor has assembled the following comments to help you prepare a revised submission. All agree that the work is of high quality and represents a significant advance in our understanding of the role of VDAC in calcium handling and cardiac physiology. A majority of the comments pasted below can be addressed by a careful revision of the manuscript. However, as pointed out by reviewer 2, the experiments do not adequately test the authors\' conclusion that Ca2+ is directly transferred between the ER and mitochondria. Additional experimentation, for example examining the effect of addition of a Ca2+ chelator.

*Reviewer \#1*:

The authors point to mitochondrial Ca2+ buffering as a protective mechanism against erratic electrical activity, and indicates a prominent role of VDAC2 as a "facilitator" of Ca2+ transfer through MCU channels. In this respect, the authors could consider investigating whether additional, possibly isoform-specific mechanisms add to the role of VDAC2 in Ca2+ permeation across the outer mitochondrial membrane.

1\) Does VDAC 2 interact with MCU and/or with some of its regulators (MICU1/2/3, EMRE or MCUR1)?

2\) Is the expression of MCU and its regulators ("MCU complex") altered in the tre mutants?

3\) Does pharmacological or molecular stimulation of VDAC2 affect the expression of the MCU complex?

*Reviewer \#2*:

The manuscript reports exciting results but needs to be improved in the following ways:

1\) The results in [Figure 3F](#fig3){ref-type="fig"} show a sample of the identification of one VDAC peptide. The mass numbers are not visible and the color code of red and blue is not clear at all especially the blue. The reader is asked to trust the authors and that is not acceptable. If space is a problem then a clear figure should be added to the supplemental file. Further, the authors report the peptides identified that are a match to VDAC 2 but they do not report what peptides were detected that did not match. What fraction of the peptides matched to VDAC2? There is an unfortunate history of attributing action to VDAC that was not due to VDAC and of identifying VDAC as a binding site when another protein was responsible. This manuscript provides other evidence that supports the conclusion that VDAC2 is the target but that does not excuse the failure to honestly report on other proteins present.

2\) The authors state "\... efsevin restores rhythmic cardiac contraction in tre by potentiating VDAC2 activity." The authors do not measure VDAC2 activity and thus this conclusion is unnecessary speculation. VDAC2 is not an enzyme and thus its action is not so easily defined in this context. The first part of the last sentence on that page is the appropriate summarizing statement.

3\) The authors state: "VDAC is an abundant channel located on the outer mitochondrial membrane serving as a primary passageway for metabolites and ions including Ca2+ ([Fig.5A](#fig5){ref-type="fig"}) ([@bib44]; 162 [@bib2]; [@bib53])." The authors fail to point out that it is the closed state of VDAC that favors Ca++ flux. That seminal publication was not cited. (Biochim Biophys Acta. 2007 Oct;1768(10):2510-5.) The state of VDAC2 as well as its presence is critical.

4\) [Figure 5](#fig5){ref-type="fig"} presents some very interesting findings but experimental details are sometimes missing and unclear. In the methods section it talks about perfusion whereas in the figure legend it is called superfusion. It is my understanding that the Fluorostar plate reader does not have perfusion capabilities but rather has the ability to make fluid additions while recording. Is that what was done? Also in the methods section it does not specify the total amount of Ca++ present in the solution, just the presumably calculated free Ca++ concentration. The actual amount of calcium present should be stated and whether the free Ca++ concentration reported is a calculated value of a measured value. Either way it is unclear why the reported value is an exact value. Is this a guess, an approximation?

In addition, the authors state "We examined whether Ca2+ released from intracellular stores could be directly transported into mitochondria through VDAC2 and whether this process could be modulated by efsevin\..." The experiments reported do not distinguish between Ca++ release into the medium and quickly taken up my mitochondria or Ca++ directly traveling between the ER and the mitochondria. That could have been tested in 3C by having a strong chelator in the medium. Thus, with the current data the authors cannot claim evidence for direct transfer. They can claim a more effective uptake of Ca++ into mitochondria after efsevin treatment.

Based on the results reported in 5B, the authors conclude that Ca++ has been transported into mitochondria in the permeabilized cells, ignoring the ER. The choice of Rhod2 was presumably based on its affinity for Ca++ and its likely saturation with Ca++ in the ER, so that observed changes are likely due to the mitochondria. The authors make no effort to point this out to the reader. It should be addressed.

5\) In the conclusions the authors state: "In this model, VDAC-dependent Ca2+ uptake controls the duration and the diffusion of cytosolic Ca2+ near the Ca2+ release sites\..." How, physically, can VDAC control the "duration of cytosolic Ca++" and the "diffusion of cytosolic Ca++"? VDAC cannot control diffusion nor can it control the duration of diffusion. What I hope the authors want to say is that VDAC2 facilitates Ca++ uptake via MCU thus reducing the local Ca++ concentration more rapidly than otherwise.
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Author response

We appreciate the reviewers' insightful and constructive suggestions to help us improve our manuscript. We have taken the reviewers' advice and revised the manuscript accordingly. In addition to clarifying the text, we revised [Figure 3](#fig3){ref-type="fig"}, present new data in [Figure 7](#fig7){ref-type="fig"}, and added three supplementary figures. Below, we address each reviewer's critiques specifically.

*Reviewer \#1 questioned whether the expression of MCU complex would be affected by NCX1 mutation or by the molecular stimulation of VDAC2*.

We address this question by in situ hybridization. We find that the expression levels of MCU and MICU1 are comparable between wild type and *tremblor* hearts with and without efsevin treatment. These findings are presented in [Figure 7-- figure supplement 1](#fig7s1){ref-type="fig"}.

*Reviewer\#1 also questioned whether VDAC2 interacts with MCU and its regulators*.

Our data that restoration of rhythmic contractions in *tremblor* requires the activity of both VDAC2 and MCU provides genetic evidence supporting a functional interaction between VDAC2 and MCU ([Figure 7B-D](#fig7){ref-type="fig"}). As the reviewer pointed out, mitochondrial Ca^2+^ transport involves MCU and its regulators. Our model would predict that manipulating the activity of other components of the MCU complex would affect the rescue effect of VDAC2 overexpression. In this revised manuscript, we provide new data showing that: 1) MICU1 is expressed in the developing heart ([Figure 7A](#fig7){ref-type="fig"}), 2) overexpression of MICU1 restores rhythmic contractions in *tremblor* and this effect requires functional VDAC2 ([Figure7E](#fig7){ref-type="fig"}), and 3) there is a synergistic effect of VDAC2 and MICU1 overexpression ([Figure 7F](#fig7){ref-type="fig"}). These findings provide evidence to support the genetic interaction between VDAC2 and the MCU complex and strengthen our hypothesis that mitochondrial Ca^2+^ buffering is beneficial to maintain cardiac rhythmicity. Future studies on the biochemical interaction between these proteins would provide further mechanistic insights.

*Reviewer \#2 made a few suggestions to* [*Figure 3*](#fig3){ref-type="fig"}:

*The reviewer thought that the sample Mass Spec image presented in* [*Figure 3F*](#fig3){ref-type="fig"} *was too small for inspection, and questioned the identities of peptides detected in our Mass Spec analysis*.

We thank the reviewer for pointing out this problem. In the original [Figure 3F](#fig3){ref-type="fig"}, we presented the sample Mass Spec image in the top panel and indicated eight peptides that match VDAC2 in the lower panel. In this revised manuscript, we rearranged [Figure 3](#fig3){ref-type="fig"} as suggested; we present peptide identity in new [Figure 3F](#fig3){ref-type="fig"} and provide an enlarged Mass Spec image in [Figure 3--figure supplement 1](#fig3s1){ref-type="fig"}.

*The reviewer also questioned whether we identified any other proteins interacting with efsevin*.

In the course of our study, we inspected six sets of data. VDAC2 was the only protein that was not present in the controls but was consistently identified from the efsevin affinity column. Vitellogenin 1 (vtg1) and NADPH quinine 1 (nqo1) were frequently found in both the control and efsevin affinity columns and thus were considered as contaminants. More importantly, our genetic analysis showed that overexpression of VDAC2 recapitulates the rescue effect of efsevin on *tremblor* and knocking down VDAC2 abolishes the responsiveness of *tremblor* to efsevin. Together, these findings support VDAC2 as a target of efsevin.

*Reviewer \#2 raised a few questions regarding the mitochondrial Ca*^*2+*^ *uptake analyses*.

*The reviewer questioned the experimental detail about the mitochondrial Ca*^*2+*^ *uptake experiment in HeLa cells*.

We apologize for the confusing description. In this experiment, we added Ca^2+^ into the samples to make the final Ca^2+^ concentration as approximately 10 μM. We have now clarified this information in the Methods and Figure Legend.

*The reviewer thought it would be helpful to point out how Rhod2 functions as a mitochondrial Ca*^*2+*^ *indicator*.

We appreciate the reviewer's concern and include this information in the Methods section.

*The reviewer thought that "examine whether Ca*^*2+*^ *released from intracellular stores could be 'locally' transported into mitochondria through VDAC2" would be a better description of our analysis*.

We thank the reviewer for the suggestion. We have revised the manuscript accordingly. In addition, we provide new data to support a local IP3R-mitochondrial Ca^2+^ transfer through VDAC2 ([Figure 5--figure supplement 1](#fig5s1){ref-type="fig"}). Previous reports have provided multiple lines of evidence in various cell types to support local Ca^2+^ transfer between IP3 receptors and mitochondria. A commonly used approach is that while both IP3-mediated and SERCA inhibition-induced discharge of the ER Ca^2+^ store cause similar global cytoplasmic \[Ca^2+^\] signal, only the IP3-induced Ca^2+^ release is rapidly propagated to the mitochondria ([@bib46], Hajnoczky et al. 1995). We now present a similar experiment with V1/V3DKO MEFs to specifically support local Ca^2+^ delivery from IP3 receptors to VDAC2/mitochondria ([Figure 5--figure supplement 1](#fig5s1){ref-type="fig"}).

*Finally, Reviewer \#2 made a few editorial suggestions (points 2, 3, 5)*.

We thank the reviewer for the suggestions. We have revised the manuscript accordingly.
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